Phaseline

Targets › COBL

COBL (Protein cordon-bleu): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Ophthalmology; next expected readout May 2027.

Plays an important role in the reorganization of the actin cytoskeleton. Regulates neuron morphogenesis and increases branching of axons and dendrites. (UniProt, O75128)

Open in Phaseline: the race on COBL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
First Affiliated Hospital of Chongqing Medical UniversityMecobalamin
Vitamin B12 derivative with neuroprotective effects
COBLPhase 4Retinal Vein Occlusion (RVO)May 2027

Conditions

Retinal Vein Occlusion (RVO) (1)

Modalities

small molecule (1)

Companies

First Affiliated Hospital of Chongqing Medical University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.